Механизмы резистентности к антибактериальным препаратам у Mycobacterium tuberculosis

Закрыть метаданные

В обзоре приведены результаты исследований механизмов действия давно применяемых и новых противотуберкулезных препаратов, а также данные о новых химических соединениях — потенциальных противотуберкулезных препаратах. Рассматриваются данные о мутациях в ряде генов возбудителя, ассоциирующиеся или связанные с резистентностью к этим лекарственным препаратам. В обзор включены данные из 67 публикаций результатов исследований, систематических обзоров и электронных ресурсов.

Ключевые слова:

Mycobacterium tuberculosis

множественная лекарственная устойчивость

механизмы действия противотуберкулезных препаратов

механизмы резистентности к лекарственным препаратам

Авторы:

Шульгина М.В.

Институт медицинского образования ФГБУ «НМИЦ им. В.А. Алмазова» Минздрава РФ

ORCID: 0000-0002-3517-7848

Дата поступления:

28.01.2024

Дата принятия в печать:

13.02.2024

Список литературы:

Interagency Coordination Group on Antimicrobial Resistance (ICGAR) No time to wait: Securing the future from drug-resistant infections — Report to the Secretary-General of the United Nations, April 2019. . Assessed January 15, 2024. https://www.who.int/antimicrobial-resistance/interagency-coordination-group/final-report/en/
Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis September, 26, 2018 A/Res/73/L.4. Assessed January 15, 2024. https://press.un.org/en/2023/ga12537.doc.htm
WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment: online annexes. World Health Organization 2022. Assessed January 15, 2024. https://www.who.int/publications/i/item/9789240048126
WHO Global tuberculosis report 2022 — Assessed January 15, 2024. https://www.who.int/publications/i/item/9789240061729
Стерликов С.А., Нечаева О.Б, Галкин В.Б., Сон И.М., Тестов В.В. Попов С.А. и др. Отраслевые и экономические показатели противотуберкулезной работы в 2018—2019 гг. Аналитический обзор основных показателей и статистические материалы. Под ред. Стерликова С.А. М.: РИО ЦНИИОИЗ; 2020. Ссылка активна 15.01.24. [электронный ресурс] https://mednet.ru/images/materials/CMT/otraslevye_i_ekonomicheskie_2018_2019_final.pdf
Almeida Da Silva P.E., Palomino J.C. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother. 2011;66(7):1417. https://doi.org/10.1093/jac/dkr173
Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis. 2003;3(1):13. https://doi.org/10.1016/s1473-3099(03)00483-3
Alame Emane AK, Guo X, Takif HE, Liu S. Drug resistance, fitness and compensatory mutations in Mycobacterium tuberculosis. Tuberculosis (Edinb.) 2021;12:102091. https://doi.org/10.1016/j.tube.2021.102091
Müller B, Borrell S, Rose G, Gagneux S. The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet. 2013;29(3):160. https://doi.org/10.1016/j.tig.2012.11.005
Gillespie SH. Tuberculosis: evolution in millennia and minutes. Biochem Soc Trans. 2007;35(5):1317. https://doi.org/10.1042/BST0351317
Aminov RI. The role of antibiotics and antibiotic resistance in nature. Environ Microbiol. 2009;11(12):2970. https://doi.org/10.1111/j.1462-2920.2009.01972.x
Dutta NK, Karakousis PC. Mechanisms of Action and Resistance of the Antimycobacterial Agents. In: Mayers D., Sobel J., Ouellette M., Kaye K., Marchaim D. (eds). Antimicrob. Drug Resist. Springer International Publishing AG, Cham. 2017;359. https://doi.org/10.1007/978-3-319-46718-4_25
Шульгина М.В., Нарвская О.В., Мокроусов И.В., Васильева И.А. Патогенные и условно-патогенные микобактерии. М.: НЬЮ-ТЕРРА; 2018. https://www.elibrary.ru/download/elibrary_37413527_15149514.pdf
Berrada ZL, Lin SY, Rodwell TC, Nguyen D, Schecter GF, Pham L, et al. Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex. Diagnostic Microbiol Inf Dis. 2016;85(2):177. https://doi.org/10.1016/j.diagmicrobio.2016.01.019
Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. Geneva World Health Organization. 2021. Assessed January 15, 2024. https://www.who.int/publications/i/item/9789240028173
Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis (WHO/CDS/TB/2018.24). Geneva: World Health Organization; 2018. Assessed January 15, 2024. https://apps.who.int/iris/bitstream/handle/10665/275469/9789241514842-eng.pdf
Liu L, Jiang F, Chen L, Zhao B, Dong J, Sun L, et al. The impact of combined gene mutations in inhA and ahpC genes on high levels of isoniazid resistance amongst katG non-315 in multidrug-resistant tuberculosis isolates from China. Emerg Microbes Infect. 2018;7(1):183. https://doi.org/10.1038/s41426-018-0184-0
Kolyva AS, Karakousis PC. Chapter 9: Old and New TB Drugs: Mechanisms of Action and Resistance Understanding Tuberculosis — New Approaches to Fighting Against Drug Resistance. Ed. Cardona P.-J. InTech; 2012;209-232. https://doi.org/10.5772/30992
Perry JA, Wright GD. Forces shaping the antibiotic resistome. Bioessays. 2014;36(12):1179-1184. https://doi.org/10.1002/bies.201400128
Marrakchi H, Ducasse S, Labesse G, Montrozier H, Margeat E, Emorine L, et al. MabA (FabG1), a Mycobacterium tuberculosis protein involved in the long-chain fatty acid elongation system FAS-II. Microbiology (Reading). 2002;148(Pt 4):951. https://doi.org/10.1099/00221287-148-4-951
Faïon L, Kamel DK, Rosangela FR, Pintiala C, Cantrelle FX, Moune M, et al. Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening. Europ J Medicin Chem. 2020;200:112440. https://doi.org/10.1016/j.ejmech.2020.112440
Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou KA, et al. Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020;12(1):27. https://doi.org/
Drug-resistant tuberculosis: A survival guide for clinicians, 3d edition. (2022 updates). Curry International Tuberculosis Center and California Department of Public Health. 2016;324. Assessed January 15, 2024. https://www.currytbcenter.ucsf.edu/products/view/drug-resistant-tuberculosis-survival-guide-clinicians-3rd-edition
Buchmeier N, Fahey RC. The mshA gene encoding the glycosyltransferase of mycothiol biosynthesis is essential in Mycobacterium tuberculosis Erdman. FEMS Microbiol Lett. 2006;264(1):74. https://doi.org/10.1111/j.1574-6968.2006.00441.x
Brossier F, Sougakoff W, Bernard C, Petrou M, Adeyema K, Pham A, et al. Molecular analysis of the embCAB Locus and embR gene involved in ethambutol resistance in clinical isolates of Mycobacterium tuberculosis in France. Antimicrob Agents Chemother. 2015;59(8):4800. https://doi.org/10.1111/j.1574-6968.2006.00441.x
Tulyaprawat O, Chaiprasert A, Chongtrakool P, Suwannakarn K, Ngamskulrungroj P. Association of ubiA mutations and high-level of ethambutol resistance among Mycobacterium tuberculosis Thai clinical isolates. Tuberculosis (Edinb). 2019;114:42. https://doi.org/10.1016/j.tube.2018.11.006
He L, Wang X, Cui P, Jin J, Chen J, Zhang W, Zhang Y. ubiA (Rv3806c) encoding DPPR synthase involved in cell wall synthesis is associated with ethambutol resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb). 2015;95(2):149. https://doi.org/10.1016/j.tube.2014.12.002
Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, 3rd. et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis: a potential mechanism for shortening the duration of tuberculosis chemotherapy. Science (New York, N.Y.). 2011;333(6049):1630. https://doi.org/10.1126/science.1208813
Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother. 2003;52(5):790. https://doi.org/10.1093/jac/dkg446
Туберкулез у взрослых. Клинические рекомендации. 2022. https://cr.minzdrav.gov.ru/recomend/16_2
Garneau-Tsodikova S, Labby KJ. Mechanisms of Resistance to Aminoglycoside Antibiotics: Overview and Perspectives. Med Chem Comm. 2016;7(1):11. https://doi.org/10.1039/C5MD00344J
Nguyen L. Antibiotic resistance mechanisms in M. tuberculosis: an update. Arch Toxicol. 2016;90(7):1585. https://doi.org/10.1007/s00204-016-1727-6
Nebenzahl-Guimaraes H, Jacobson KR, Farhat MR, Murray MB. Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2014;69(2):331. https://doi.org/10.1093/jac/dkt358
Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry. 2014;35(10):1565. https://doi.org/10.1021/bi5000564
Al Matar M, Al Mandeal H, Var I, Kayar B, Köksal F. New drugs for the treatment of Mycobacterium tuberculosis infection. Biomed & Pharmacother. 2017;91:546. https://doi.org/10.1016/j.biopha.2017.04.105
Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother. 2012;67(4):819. https://doi.org/10.1093/jac/dkr566
Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Böttger EC. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother. 2012;67(5):1088. https://doi.org/10.1093/jac/dks033
Disratthakit A, Prammananan T, Tribuddharat C, Thaipisuttikul I, Doi N, Leechawengwongs M. et al. Role of gyrB mutations in pre-extensively and extensively drug-resistant tuberculosis in Thai clinical isolates. Antimicrob Agents Chemother. 2016;60:5189. https://doi.org/10.1128/AAC.00539-16
Ajileye A, Alvarez N, Merker M, Walker TM, Akter S, Brown K, et al. Some synonymous and nonsynonymous gyrA mutations in Mycobacterium tuberculosis lead to systematic false-positive fluoroquinolone resistance results with the Hain GenoType MTBDRsl assays. Antimicrob Agents Chemother. 2017;61(4):e02169-16. https://doi.org/10.1128/AAC.02169-16
Zhang X, Liu L, Zhang Y, Dai G, Huang H, Jin Q. Genetic determinants involved in p-aminosalicylic acid resistance in clinical isolates from tuberculosis patients in northern China from 2006 to 2012. Antimicrob Agents Chemother. 2015;59(2):1320. https://doi.org/10.1128/AAC.03695-14
Zhao F, Wang XD, Erber LN, Luo M, Guo AZ, Yang SS, et al. Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014;58(3):1479. https://doi.org/10.1128/AAC.01775-13
Zheng J, Rubin EJ, Bifani P, Mathys V, Lim V, Au M, et al., para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. J Biol Chem. 2013;88(32):23447. https://doi.org/10.1074/jbc.M113.475798
Chen J, Zhang S, Cui P, Shi W, Zhang W, Zhang Y. Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2017;72(12):3272. https://doi.org/10.1093/jac/dkx316
Xu J, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL. Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis. Antimicrob, Agents Chemother. 2021;65(4):e02418-20. https://doi.org/10.1128/AAC.02418-20
Kadura S, King N, Nakhoul M, Zhu H, Theron G, Köser CU, et al. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs Bedaquiline, Clofazimine, Linezolid, Delamanid and Pretomanid. J Antimicrob Chemother. 2020;75:2031. https://doi.org/10.1093/jac/dkaa136
Almeida D, Ioerger T, Tyagi S, Li SY, Mdluli K, Andries K, et al. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2016;v.60(8):4590. https://doi.org/10.1128/AAC.00753-16
Almeida DV, Converse PJ, Nuermberger EL. Mutations in Rv0678 Reduce Susceptibility of Mycobacterium tuberculosis to the DprE1 Inhibitor TBA-7371. Antimicrob Agents Chemother. 2023;67(3):e0005223. https://doi.org/10.1128/aac.00052-23
Mokrousov I, Akhmedova G, Molchanov V, Fundovnaya E, Kozlova E, Ostankova Y, et al. Frequent acquisition of Bedaquiline resistance by epidemic extensively drug-resistant Mycobacterium tuberculosis strains in Russia during long-term treatment. Clin Microbiol Infect. 2021;27:478. https://doi.org/10.1016/j.cmi.2020.08.030
Xu J, Wang B, Hu M, Huo F, Guo S, Jing W, et al. Primary Clofazimine and Bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2017;61(6):e00239-17. https://doi.org/10.1128/AAC.00239-17
Zheng H, He W, Jiao W, Xia H, Sun L, Wand S, et al. Molecular characterization of multidrug-resistant tuberculosis against Levofloxacin, Moxifloxacin, Bedaquiline, Linezolid, Clofazimine, and Delamanid in Southwest of China. BMC Infect Dis. 2021;21:330. https://doi.org/10.1186/s12879-021-06024-8
Cellitti SE, Shaffer J, Jones DH, Mukherjee T, Gurumurthy M, Bursulaya B, et al. Structure of Ddn, the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824. Structure. 2012;20(1):101. https://doi.org/10.1016/j.str.2011.11.001
Wang F, Yuan Q, Chen F, Pang J, Pan C, Xu F, Chen Y. Fundamental Mechanisms of the Cell Death Caused by Nitrosative Stress. Front Cell Dev Biol. 2021;9:742483. https://doi.org/10.3389/fcell.2021.742483
Jirapanjawat T, Ney B, Taylor MC, Warden AC, Afroze S, Russell RJ, et al. The Redox Cofactor F420 Protects Mycobacteria from Diverse Antimicrobial Compounds and Mediates a Reductive Detoxification System. Appl Environ Microbiol. 2016;82(23):6810. https://doi.org/10.1128/AEM.02500-16
Rifat D, Li SY, Ioerger T, Shah K, Lanoix JP, Lee J, et al. Mutations in fbiD (Rv2983) as a novel determinant of resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2020;65(1):e01948-20. https://doi.org/10.1128/AAC.01948-20
Battaglia S, Spitaleri A, Cabibbe AM, Meehan CJ, Utpatel C, Ismail N, et al. Characterization of genomic variants associated with resistance to Bedaquiline and Delamanid in naive Mycobacterium tuberculosis clinical strains. J Clin Microbiol. 2020;58:e01304-20. https://doi.org/10.1128/JCM.01304-20
Haver HL, Chua A, Ghode P, Lakshminarayana SB, Singhal A, Mathema B, et al. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59:5316. https://doi.org/10.1128/AAC.00308-15
Rupasinghe P, Reenaers R, Vereecken J, Mulders W, Cogneau S, Merker M, et al. Refined understanding of the impact of the Mycobacterium tuberculosis complex diversity on the intrinsic susceptibility to pretomanid. Microbiol Spectr. 2024;e00070-24. https://doi.org/10.1128/spectrum.00070-24
Zhang S, Chen J, Cui P, Shi W, Shi X, Niu H, et al. Mycobacterium tuberculosis mutations associated with reduced susceptibility to Linezolid. Antimicrob Agents Chemother. 2016;60(4):2542. https://doi.org/10.1128/AAC.02941-15
World Health Organization. Status of the pipeline for new TB products//-2022. Assessed January 15, 2024. https://www.who.int/observatories/global-observatory-on-health-research-and-development/analyses-and-syntheses/tuberculosis/analysis-of-tb-r-d-pipeline
Stop TB Partnership Working group on new drugs. Assessed January 15, 2024. www.newtbdrugs.org
Pidot SJ, Rizzacasa MA. The Nargenicin Family of oxa-bridged macrolide antibiotics. Chem Europe. 2020;26(13):2780. https://doi.org/10.1002/chem.201904053
Dartois VA, Rubin EJ. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat Rev Microbiol. 2022;20:685. https://doi.org/10.1038/s41579-022-00731-y
Black TA, Ulrike K, Buchwald UK. The pipeline of new molecules and regimens against drug-resistant tuberculosis. J Clin Tuberc Other Mycobact Dis. 2021;25:100285. https://doi.org/10.1016/j.jctube.2021.100285
Bonsa Z, Tadesse M, Balay G, Kebede W, Abebe G. Discordance between genotypic and phenotypic methods for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis and the correlation with patient treatment outcomes J Clin Tuberculosis and Other Mycobact Dis. 2024;34:100410. https://doi.org/10.1016/j.jctube.2023.100410
Rieder HL, Van Deun A. Rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis. Int J Tuber Lung Dis. 2017;21(1):123. https://doi.org/10.5588/ijtld.16.0619
Valafar SJ. Systematic Review of Mutations Associated with Isoniazid Resistance Points to Continuing Evolution and Subsequent Evasion of Molecular Detection, and Potential for Emergence of Multidrug Resistance in Clinical Strains of Mycobacterium tuberculosis. Antimicrob Agents and Chemoth. 2021;65(3):e02091. https://doi.org/e02091-20
Domínguez J, Boeree MJ, Cambau E, Chesov D, Conradie F, Cox V, et al. TBnet and RESIST-TB networks. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infect Dis. 2023;23(4):e122. https://doi.org/10.1016/S1473-3099(22)00875-1

Закрыть метаданные